Premium
P4‐193: Effect of TREM2 and PLD3 in an Alzheimer's disease family history cohort: The wisconsin registry for Alzheimer's prevention (WRAP)
Author(s) -
Engelman Corinne D.,
Darst Burcu F.,
Koscik Rebecca L.,
Johnson Sterling C.
Publication year - 2015
Publication title -
alzheimer's and dementia
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 6.713
H-Index - 118
eISSN - 1552-5279
pISSN - 1552-5260
DOI - 10.1016/j.jalz.2015.08.021
Subject(s) - family history , trem2 , cohort , medicine , asymptomatic , alzheimer's disease , medical history , risk factor , disease , psychology , microglia , inflammation
Background:TREM2 is discussed as a new genetic risk factor for Alzheimer’s dementia. This study aims to evaluate the impact of rare TREM2 variants (A105Rfs*84,D87N,Q33*, R47H, R62C, R62H, T85I) on cognitive decline and time to Alzheimer’s dementia. Methods: AgeCoDe is a GP based, prospective longitudinal study. Mean age carriers: 83, female: 82%, mean age non-carriers: 80, 65 % females. Subjects included three groups: demented TREM2 carriers (n1⁄410); age, gender, education, dementia time point and MMSE baseline performance matched demented noncarriers (n1⁄4270), and cognitively normal non-carriers (n1⁄43316). Using growth curve modeling of decline, group trajectories of MMSE were calculated for cognitively normal subjects and demented TREM2 non-carriers. Confidence intervals for the trajectories of cognitively normal non-carrier group as well as the demented TREM2 non-carrier group were overlayed with observed MMSE group trajectories of the demented TREM2 carriers. Time to dementia was compared for demented non-carriers and carriers. Results:The TREM2 carrier group did not differ in MMSE decline from the demented TREM2 non-carriers, whereas the cognitively normal group differed much from the TREM2 carriers. Moreover, demented TREM2 carriers and demented non carriers did not differ in the time to dementia. Conclusions: In higher age, the effect of TREM2 is not as pronounced as previous studies suggest on MMSE decline in early onset AD, whereas it can still be observed in comparison to cognitively healthy.